Novartis is putting down $30 million, with a potential $772 million on the line, to work with BioArctic’s tech to find a new ...

The National Cancer Institute (NCI) is ending its support for a 26-year-old push to advance clinical trials for children with ...

Regeneron has reported a phase 3 win in generalized myasthenia gravis, positioning the biotech to file for FDA approval of its siRNA candidate in the increasingly competitive neuromuscular disease.

Another cell therapy biotech has run out of steam, this time before ever reaching the clinic. | Another cell therapy biotech ...

Gumokimab, also called AK111, is an anti-IL-17A monoclonal antibody that Akeso has already tested out in a separate phase 3 ...

After Eli Lilly’s phase 3 data drop for its oral GLP-1 asset orforglipron earlier this month, the Indianapolis drugmaker has unveiled the second half of the data package that will support the med’s | ...

Amid a frozen-over IPO landscape, LB Pharmaceuticals has filed to go public to fund a pivotal schizophrenia study for its ...

With the FDA’s go-ahead, Coya plans to launch a multicenter phase 2 trial of COYA 302 in patients with ALS, CEO Arun ...

The candidates are sourced from Arnatar’s next-gen RNA discovery engine, dubbed DARGER for dual-functional antisense RNA for ...

At AbbVie, bretisilocin will slot into a well-established neuroscience unit. AbbVie has deals with Gedeon Richter, the source ...

PDS Biotech has reported final phase 2 data on PDS0101 in the tough-to-treat head and neck cancer setting, linking a combination of the immunotherapy and Keytruda to median overall survival (OS) of 39 ...

By: Raymund Santos, Senior Manager, Quality Control Bioanalytics, AGC BiologicsAelén Mabillé, Manager, Quality Control Raw ...